CyanVac and Blue Lake Biotechnology Announce First Participant Dosed in a Phase 1 Clinical Trial to Evaluate its CVXGA1 Intranasal COVID-19 Vaccine

By In The News
September 27, 2021 in The Headlines

Followers 0

Recommended Posts

In The News

Posted September 27, 2021

- Share

Posted September 27, 2021

ATHENS, Ga. and LOS ALTOS, Calif., Sept. 27, 2021 /PRNewswire/ -- CyanVac LLC and its subsidiary, Blue Lake Biotechnology, Inc., clinical-stage biopharmaceutical companies developing vaccines using a proprietary transformational parainfluenza virus 5 (PIV5)-based vector, today announced...

View the full article

Link to comment

Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign in

Already have an account? Sign in here.

Followers 0

Go to topic listing

Most Contributions
1. In The News
  219911
2. Jaydee
  16794
3. Kip Powick
  12213
4. deicer
  12196
5. dagger
  9595
Tell a friend
Love The Airline Website? Tell a friend!
- Email
- Share
Forum Statistics
- Total Topics
  
  270.2k
- Total Posts
  
  558.8k

Sign In

CyanVac and Blue Lake Biotechnology Announce First Participant Dosed in a Phase 1 Clinical Trial to Evaluate its CVXGA1 Intranasal COVID-19 Vaccine

Recommended Posts

In The News

Link to comment

Share on other sites

Create an account or sign in to comment

Create an account

Sign in

Most Contributions

Tell a friend

Forum Statistics

Browse

Activity

Support